There is a limit on how many times a mammal can be cloned before suffering "mutational meltdown," Japanese scientists have ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...

Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea's proprietary in vivo CAR T platform -- Peer-reviewed publication demonstrates stable, cell-specific transgene expression ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...

Jackson Lab plans to renovate an existing 3,500-square-foot facility on the Bar Harbor campus, expand capacity and meet ...

Scientists at Oregon Health & Science University have developed a new molecule that could open the door to treating triple-negative breast cancer, one of the most aggressive and difficult-to-treat ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Chennai, March 7 -- Highlights: ...

Trastuzumab is a common treatment for various HER2-positive cancers. It is an antibody that specifically binds to HER2, a problematic protein over-expressed on cancer cells that signals for nonstop ...

Humanized immune system (HIS) mouse models are increasingly central to immuno-oncology and immune-modulating drug development, yet study-to-study variability can limit translational confidence. This ...